Santhosh A Upadhyaya1, Yahya Ghazwani1, Shengjie Wu2, Alberto Broniscer1, Fredrick A Boop3,4, Amar Gajjar1, Ibrahim Qaddoumi1. 1. Division of Neuro-Oncology, Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee. 2. Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee. 3. Department of Surgery, St. Jude Children's Research Hospital, Memphis, Tennessee. 4. Department of Neurosurgery, LeBonheur Children's Hospital, Memphis, Tennessee.
Abstract
BACKGROUND: While pediatric low-grade glioma/glioneuronal tumors (LGG/LGGNTs) are considered slow-growing, indolent tumors with excellent long-term prognosis, mortality due to the disease is not unknown. Few studies have addressed the cause of death in this population. METHODS: Retrospective review of clinicopathologic and radiologic data for children 21 years or younger with LGG/LGGNT who died at St. Jude Children's Research Hospital between April 1985 and June 2015. Our primary objective was to determine the causes and timing of mortality in affected children. RESULTS: For the 87 eligible patients, median age at diagnosis was 7.7 years (range, 0.21-21 years), median age at death was 14.26 years (range, 0.58-32 years), and median time to death from diagnosis was 4.02 years (range, 0.21-24 years). Midbrain/thalamus was the most common tumor location (n = 34), followed by suprasellar/hypothalamic (n = 18) and cerebrocortical (n = 13). Astrocytoma not otherwise specified (n = 24), pilocytic astrocytoma (n = 23), and fibrillary astrocytoma (n = 11) were the predominant histologic diagnoses. Causes of death included progressive primary disease (PD) (n = 43), progression of PD with histological features of a high-grade glioma at progression or at autopsy (PD-HGG) (n = 15), second cancer (n = 3), suicide (n = 4), and vehicular accident (n = 3). Among the 15 patients with PD-HGG, 12 received radiation therapy before histologic confirmation of progression. CONCLUSIONS: PD and PD-HGG contributed to 66% of the mortality in our patient cohort. Early psychological intervention should be included as part of the multidisciplinary management approach of children with LGG/LGGNT to reduce the risk of suicide in vulnerable subjects.
BACKGROUND: While pediatric low-grade glioma/glioneuronal tumors (LGG/LGGNTs) are considered slow-growing, indolent tumors with excellent long-term prognosis, mortality due to the disease is not unknown. Few studies have addressed the cause of death in this population. METHODS: Retrospective review of clinicopathologic and radiologic data for children 21 years or younger with LGG/LGGNT who died at St. Jude Children's Research Hospital between April 1985 and June 2015. Our primary objective was to determine the causes and timing of mortality in affected children. RESULTS: For the 87 eligible patients, median age at diagnosis was 7.7 years (range, 0.21-21 years), median age at death was 14.26 years (range, 0.58-32 years), and median time to death from diagnosis was 4.02 years (range, 0.21-24 years). Midbrain/thalamus was the most common tumor location (n = 34), followed by suprasellar/hypothalamic (n = 18) and cerebrocortical (n = 13). Astrocytoma not otherwise specified (n = 24), pilocytic astrocytoma (n = 23), and fibrillary astrocytoma (n = 11) were the predominant histologic diagnoses. Causes of death included progressive primary disease (PD) (n = 43), progression of PD with histological features of a high-grade glioma at progression or at autopsy (PD-HGG) (n = 15), second cancer (n = 3), suicide (n = 4), and vehicular accident (n = 3). Among the 15 patients with PD-HGG, 12 received radiation therapy before histologic confirmation of progression. CONCLUSIONS:PD and PD-HGG contributed to 66% of the mortality in our patient cohort. Early psychological intervention should be included as part of the multidisciplinary management approach of children with LGG/LGGNT to reduce the risk of suicide in vulnerable subjects.
Authors: Tore Stokland; Jo-Fen Liu; James W Ironside; David W Ellison; Roger Taylor; Kathryn J Robinson; Susan V Picton; David A Walker Journal: Neuro Oncol Date: 2010-09-22 Impact factor: 12.300
Authors: Tara M Brinkman; Cori C Liptak; Brian L Delaney; Christine A Chordas; Anna C Muriel; Peter E Manley Journal: J Neurooncol Date: 2013-04-27 Impact factor: 4.130
Authors: Alberto Broniscer; Suzanne J Baker; Alina N West; Melissa M Fraser; Erika Proko; Mehmet Kocak; James Dalton; Gerard P Zambetti; David W Ellison; Larry E Kun; Amar Gajjar; Richard J Gilbertson; Christine E Fuller Journal: J Clin Oncol Date: 2007-02-20 Impact factor: 44.544
Authors: Maria W Gunnes; Rolv T Lie; Tone Bjørge; Sara Ghaderi; Astri Syse; Ellen Ruud; Finn Wesenberg; Dag Moster Journal: Int J Cancer Date: 2016-10-26 Impact factor: 7.396
Authors: Sonika Dahiya; Devon H Haydon; David Alvarado; Christina A Gurnett; David H Gutmann; Jeffrey R Leonard Journal: Acta Neuropathol Date: 2013-04-23 Impact factor: 17.088
Authors: Pratiti Bandopadhayay; Guillaume Bergthold; Wendy B London; Liliana C Goumnerova; Andres Morales La Madrid; Karen J Marcus; Dongjing Guo; Nicole J Ullrich; Nathan J Robison; Susan N Chi; Rameen Beroukhim; Mark W Kieran; Peter E Manley Journal: Pediatr Blood Cancer Date: 2014-01-30 Impact factor: 3.167
Authors: Guendalina Gentile; Stefano Tambuzzi; Raffaella Calati; Riccardo Zoja Journal: Int J Environ Res Public Health Date: 2022-01-12 Impact factor: 3.390